Literature DB >> 19443138

Comparing overdose mortality associated with methadone and buprenorphine treatment.

James R Bell1, Bethany Butler, Anne Lawrance, Robert Batey, Pia Salmelainen.   

Abstract

AIM: To compare overdose mortality associated with methadone and buprenorphine treatment for opioid dependence.
METHODS: Data linkage study. Since 1 April 2006, the Division of Analytic Laboratories (DAL) has routinely tested all New South Wales (NSW) coronial post-mortem samples for both methadone and buprenorphine. Names of all methadone or buprenorphine-positive cases between April and December 2006 inclusive were linked to the National Coroners Information System (NCIS) database, which provided information on cause of death, autopsy findings and circumstances of death. Names were linked to the Pharmaceutical Services Branch Drugs of Addiction System (PHDAS) database to identify whether people were in treatment, and in decedents not registered in treatment, the source of methadone or buprenorphine was presumed to be diversion from treatment programs. Mean number in treatment during 2006 for methadone and buprenorphine were derived from the PHDAS database. Rate of opioid overdose per thousand people in treatment were calculated for methadone and buprenorphine.
RESULTS: In the 9-month period there were 13,718 in methadone treatment and 2716 people in buprenorphine. There were 60 sudden deaths positive for methadone (32 in-treatment) and 7 buprenorphine-positive decedents (none in treatment). Most out-of-treatment deaths occurred in people with known histories of drug misuse. Forty-three methadone positive cases - 19/32 in treatment, and 24/28 out-of-treatment - and 2 of the 7 buprenorphine-positive deaths were due to overdose. The risk of overdose death per thousand people in treatment was lower for buprenorphine than for methadone (RR 4.25 [1.03, 17.54]).
CONCLUSION: In this short-term study, buprenorphine was associated with lower overdose risk than methadone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443138     DOI: 10.1016/j.drugalcdep.2009.03.020

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  54 in total

1.  Buprenorphine versus methadone use in opiate detoxification, are there other factors that should be considered?

Authors:  Hardeep K Bhupal
Journal:  Br J Gen Pract       Date:  2012-02       Impact factor: 5.386

Review 2.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  Intravenous methadone application as a serious risk factor for an overdose death: methadone-related fatalities in Hamburg from 2007 to 2012.

Authors:  Stefanie Iwersen-Bergmann; Hilke Jungen; Hilke Andresen-Streichert; Alexander Müller; Sally Elakkary; Klaus Püschel; Axel Heinemann
Journal:  Int J Legal Med       Date:  2014-05-25       Impact factor: 2.686

4.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

5.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

6.  Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.

Authors:  Marc J Fishman; Li-Tzy Wu; George E Woody
Journal:  Am J Psychiatry       Date:  2011-07       Impact factor: 18.112

7.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

8.  Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland.

Authors:  Becky L Genberg; Mirinda Gillespie; Charles R Schuster; Chris-Ellyn Johanson; Jacquie Astemborski; Gregory D Kirk; David Vlahov; Shruti H Mehta
Journal:  Addict Behav       Date:  2013-08-17       Impact factor: 3.913

9.  Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model.

Authors:  Jonathan E Fried; Sanjay Basu; Russell S Phillips; Bruce E Landon
Journal:  Ann Fam Med       Date:  2020-11       Impact factor: 5.166

Review 10.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Authors:  Jean Bonhomme; Ruth S Shim; Richard Gooden; Dawn Tyus; George Rust
Journal:  J Natl Med Assoc       Date:  2012 Jul-Aug       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.